Phase 2 N=18 Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants
Prader Willi Syndrome
Primary: Occurence of Adverse Event — 10; 9; 6 number of adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
Malaria, Falciparum · Malaria, Vivax
Primary: Crude Adequate Clinical and Parasitological Response (ACPR) — 90; 100 percentage of participants
Phase 2 N=183 A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study — 80.9 percentage of participants
Phase 2 N=124 Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
Tourette Syndrome in Children · Tourette Syndrome in Adolescence
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Their Relationship (Unrelated, Possibly Related, or Probably Related) — 84; 2; 44…
Phase 2 N=100 Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
Gastric Cancer
Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)…
Phase 2 N=232 UW Withdraw From Tobacco Study
Tobacco Dependence
Primary: Change in Total Score on Wisconsin Smoking Withdrawal Scale2 Long (WSWS2-L) — 2.64; 2.36; 2.29; 2.69 score on a scale
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Phase 2 N=99 A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
Diabetic Macular Edema
Primary: Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS)…
Phase 2 N=137 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants
Phase 2 N=44 Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Parkinson's Disease · Constipation
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events. — 9; 16; 1 Participants
Phase 2 N=20 Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
Advanced Solid Tumors
Primary: Dose Verification and PK Sub-study: Number Participants With Adverse Events — 20; 54; 9; 21 Participants
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
Phase 2 N=33 A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Brain Neoplasms
Primary: Establish a Safe Dose for Oral 5-ALA Administration — 0; 0; 0; 0 Dose Limiting Toxicity
Phase 2 N=56 A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
Primary: Response Rate of Patients Receiving Crenolanib Therapy — 8; 3; 4; 1 Participants
Phase 2 N=14 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Metastatic Malignant Neoplasm in the Liver · Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) — 0; 0; 8; 5 Participants